Wastewater analysis
For water monitoring professionals, laboratories and suppliers, however, it points to a much larger issue: the growing need for defensible evidence on which products, substances and sectors are actually responsible for micropollutants in wastewater.
The revised Urban Wastewater Treatment Directive entered into force in January 2025 and introduced a new extended producer responsibility system for producers of medicinal and cosmetic products.
Under the rules, EU countries must ensure that those producers cover at least 80% of the cost of removing micropollutants from urban wastewater by 31 December 2028.
The system is linked to the deployment of quaternary treatment, an additional treatment stage designed to remove a broader range of trace organic pollutants that are not adequately captured by conventional wastewater treatment.
The Commission’s new initiative concerns exemptions from that EPR system.
The Directive already allows producers to be exempt where they can demonstrate that the substances in their products fall below a one-tonne annual threshold, are rapidly biodegradable in wastewater, or do not generate micropollutants in wastewater at the end of their life.
The Commission is now expected to define more detailed criteria for how those exemptions should work in practice.
For the monitoring sector, this is where the policy becomes technically significant.
An exemption regime cannot operate on assertion alone. Producers seeking exemption will need evidence on substance quantities, biodegradability, hazardousness, persistence, wastewater fate and the likelihood that a product generates micropollutants after use.
That creates a direct role for environmental laboratories, chemical testing providers, wastewater researchers, data-management platforms and consultants able to connect product composition with wastewater behaviour.
The measure also sits within a politically contested area. Pharmaceutical and cosmetics companies have argued that the current EPR model places too much responsibility on two sectors and does not sufficiently reflect the contribution of other sources of micropollutants.
In the Commission’s own summary of stakeholder views, cosmetics and pharmaceutical sectors called for the EPR provisions to be frozen while costs and toxic loads were reassessed, while chemicals companies and associations called for common criteria for products that do not generate micropollutants.
Water utilities, cities and municipalities took the opposite view, defending EPR and the polluter-pays principle, warning that without producer contributions, quaternary treatment investments could increase water tariffs or pressure public budgets.
That tension makes measurement more important, not less. If the EU moves towards clearer exemption criteria, the debate will increasingly turn on what can be measured, modelled and verified.
Which substances persist through wastewater treatment? Which degrade rapidly? Which form harmful transformation products? Which product categories contribute materially to treatment costs? These are not only legal or policy questions. They are analytical questions.
The implications are likely to reach several parts of the monitoring market. Wastewater laboratories may see greater demand for trace-level analysis of pharmaceuticals, cosmetic ingredients and transformation products.
Testing providers may need to support biodegradability and hazardousness assessments. Utilities and regulators may require stronger influent and effluent monitoring to understand micropollutant loads before and after quaternary treatment.
Digital reporting systems may also become more important as producers, producer responsibility organisations and authorities exchange data on product quantities, substance characteristics and exemptions.
The quaternary treatment rollout itself will reinforce this demand. Advanced treatment technologies such as activated carbon, ozonation and related polishing processes require reliable monitoring to demonstrate performance, optimise operating costs and avoid unintended effects such as problematic by-products.
If EPR contributions are tied to the cost of installing and operating these systems, then evidence on treatment performance and micropollutant removal will become central to both compliance and cost allocation.
For producers, the exemption initiative may offer a route to reduce financial exposure, but only where the supporting evidence is strong. For utilities, it raises the question of whether exemptions could narrow the funding base for quaternary treatment.
For regulators, it creates the challenge of applying exemption criteria consistently across Member States. For laboratories and monitoring suppliers, it creates a practical opportunity: helping all sides move from broad claims about pollution responsibility to traceable, substance-specific evidence.
The wider direction is clear. EU wastewater policy is moving beyond traditional measures of organic load, nutrients and suspended solids. It is increasingly concerned with trace contaminants, product lifecycles, chemical persistence and the cost of advanced treatment.
The proposed exemption rules are therefore not a side issue. They are part of a broader shift towards more detailed chemical accountability in urban wastewater.
For monitoring professionals, the core message is simple. As the EU refines who pays for micropollutant removal, the quality of the evidence will matter. Laboratories, instrumentation providers and data specialists will be essential to proving whether products generate micropollutants, whether exemptions are justified, and whether quaternary treatment is delivering the environmental protection promised by the Directive.
IET 36.3 May
Product directory
.jpg)
